COVINGTON & BURLING

Comment: Primarily reputed for his in-depth expertise in clinical research, pharmacovigilance and compliance, lawyer and doctor Koyuncu heads the recommended Brussels pharma practice. The team supporting this German industry specialist also profits from the firm’s US network and increasingly advises US companies and their German subsidiaries on regulatory and strategic matters in Europe. The practice also has these contacts to thank for the instruction in its first AMNOG proceedings. Equally, Covington also advises a client base rooted in Germany, which it recently expanded: new assignments include advice to a medical product manufacturer in a liability lawsuit and to a manufacturer of disinfection agents on demarcation issues. Work in the field of compliance in connection with the new anticorruption law has recently stepped up a gear, as have instructions related to medical product law. That said, the firm is still facing a severe shortage of staff: following the departure of an experienced associate (moved in-house), Covington – like many competitors – is now desperately on the lookout for up-and-coming talent.
Strengths: Well-founded, international industry expertise, esp. in pharmacovigilance.
Recommended: Dr. Dr. Adem Koyuncu (“expensive but good lawyer”, “fab background knowledge as doctor and lawyer, highly satisfied, responds quickly”, clients; “highly competent”, competitor), Peter Bogaert.
Practice: All-round advice on research-focused international pharma and medical product manufacturers, incl. on regulatory matters, approval procedures, reimbursement of costs, clinical trials, and pharma advertising litigation. Increasingly compliance and data protection/e-health. Also industry-specific antitrust and patent law. Advice on transactions. (Lawyers admitted in Germany: 2 partners, 3 associates)
Clients: ?? Boehringer Ingelheim on splitting off from veterinary medicine products; Eucope, Efpia and EuropaBio in infringement procedure against Italy due to off-label use; Roche Group in regulatory investigation proceedings on EU penalties regulation; ATMP manufacturer against Paul-Ehrlich-Institut in dispute concerning authorization of a medicinal product for novel therapies; biotech company on compliance; manufacturer in the field of dentistry on compliance and pharma advertising.
  • Teilen